Informa
기조 세션

Paul Csiszar

경쟁법 시행에 관한 유럽위원회의 최신 견해

DG Competition, European Commission, Belgium

5월 21일
Show Filter
08:00 - 08:50

Registration

More
Showing of Streams
10:40 - 11:10

Networking Break

More
Showing of Streams
12:40 - 14:10

Networking Lunch Break

More
Showing of Streams
15:30 - 16:00

Networking Break

More
Showing of Streams
17:25 - 18:15

Close of Competition Law and Patent Litigation Day

More
Showing of Streams
20:15 - 21:15

Networking Dinner

More
08:00 - 08:50 50 mins
Registration
08:50 - 09:00 10 mins
Competition Law and Patient Litigation
Introduction from Chairperson
  • Melanie Thill-Tayara - Antitrust/Competition Partner, Dechert LLP, France
09:00 - 09:40 40 mins
Info
Competition Law and Patient Litigation
Update from EU Commission on Competition Law Enforcement
  • Paul Csiszar - Director, DG Competition, European Commission, Belgium
  • Recent updates in the EU pharmaceutical Law sector on competition law enforcement
  • Insight into abusive dominance through excessive pricing
  • Latest developments on reverse payment settlements
09:40 - 10:40 60 mins
Info
Competition Law and Patient Litigation
INTERACTIVE DISCUSSION FORUM: Excessive Pricing in the Pharmaceutical Industry
  • Ingrid Vandenborre - Partner, Skadden, Arps, Slate, Meagher & Flom LLP and Affiliates, Belgium
  • Wolf Sauter - Expert, Netherlands Authority for Consumers and Markets (ACM), The Netherlands
  • Molly Herron - Senior Legal Counsel, Antitrust EMEA, Novartis International AG, Switzerland
  • Update on abusive dominance through excessive pricing case law
  • Practical advice following decisions and developments in recent cases
  • What constitutes excessive: identifying appropriate value indicators for originator products and understanding value to whom and compared to what
10:40 - 11:10 30 mins
Networking Break
11:10 - 12:10 60 mins
Info
Competition Law and Patient Litigation
INTERACTIVE DISCUSSION FORUM: Reverse Payment Patent Settlements
  • Geoff Steadman - Project Director, Competition & Markets Authority (CMA), UK
  • Rainer Becker - Head of Unit, DG Competition, European Commission, Belgium
  • James Killick - Partner, White & Case LLP, Belgium
  • Insight into the Lundbeck and Servier case: practical implications for patent settlements and market definition
  • Acquisitions of technology: can this be considered an abuse of a dominant position?
  • How do you define the relevant market from a competition law perspective to define dominance?
12:10 - 12:40 30 mins
Info
Competition Law and Patient Litigation
Update on Parallel Trade in a Post Brexit Era
  • Jacob Westin - Legal Counsel, Shire Pharmaceuticals, Sweden
  • Recent competition law rulings and case law for parallel trade: update on dual pricing
  • Drivers of parallel trade across Europe, key risks and implications
  • Exploring the impact of Brexit on the EU market and parallel trade practices
  • Models and approaches for pharmaceutical companies: what opportunities and risks will Brexit offer?
12:40 - 14:10 90 mins
Networking Lunch Break
14:10 - 14:50 40 mins
Info
Competition Law and Patient Litigation
DUAL DIALOGUE: Examining Product Hopping: Abusive Dominance or Product Innovation?
  • David Hull - Partner, Van Bael & Bellis LLP, Belgium
  • Angela Staunton - Vice President, Law, Patents & Compliance - Pharmaceuticals, Bayer Healthcare AG, Germany
  • Examining cases, rulings and review for product hopping as a lifecycle management strategy
  • Update on the expansion of antitrust scrutiny on product lifecycle strategies
  • Strategies to minimise competition law risks and protect your product
14:50 - 15:30 40 mins
Info
Competition Law and Patient Litigation
INTERACTIVE DISCUSSION FORUM: Assessing the Current Status of SPCs
  • Brian Cordery - Partner, Bristows LLP, UK
  • Nicolas Ruiz - Intellectual Property Head, European Patent Attorney, Esteve, Spain
  • Update on the law of "protected by a basic patent force": how is Gilead being applied by National Courts and Patent Offices? Royalty Pharma and Janssen references
  • The latest on SPCs based on 3rd party Mas: what is the direction of travel?
  • SPCs for novel and inventive formulations: the Abraxis decision
  • SPCs for medical devices and combined medical devices/medicinal products - the CJEU decision in Boston Scientific
  • Reform of SPC law - the Max Planck report and other initiatives: evaluating the proposed manufacturing exemption
15:30 - 16:00 30 mins
Networking Break
16:00 - 16:40 40 mins
Info
Competition Law and Patient Litigation
DUAL DIALOGUE: Patent Relief - Injunctions, Arrow Declarations, Cross Border Declarations and Injunctions
  • Benoit Strowel - Managing Partner, Hoyng Rokh Monegier LLP, Belgium
  • Paul Inman - Partner, Gowling WLG LLP, UK
  • Examining recent trends in the granting of relief by the major European Patents Courts
  • Are final injunctions no longer to be the norm following a finding that a patent is valid and infringed?
  • What role could compulsory licences pay?
  • Cross-border relief
  • Update on Arrow declarations
16:40 - 17:20 40 mins
Info
Competition Law and Patient Litigation
DUAL DIALOGUE: Second Medical Use Patents
  • Hiroshi Sheraton - Partner, Baker & McKenzie LLP, UK
  • Jennifer Sunderland - Senior Patent Litigation Counsel, Global Litigation, Mylan, UK
  • Examining the UKSC decision in the pregabalin case and the implications for plausibility, amendment of patents and cross-label use
  • Practical steps to be taken when enforcing a second medical use patent
  • How much data needs to be included in a patent? How to find the sweet-spot in which to file an application
17:20 - 17:25 5 mins
Competition Law and Patient Litigation
Chairperson's Closing Remarks
17:25 - 18:15 50 mins
Close of Competition Law and Patent Litigation Day
20:15 - 21:15 60 mins
Networking Dinner

* 주최측 사정에 따라 사전 예고없이 프로그램이 변경될 수 있습니다.